



Attorney Docket No. 1293.1169

THE UNITED STATES PATENT AND TRADEMARK OFFICE

	THE OWNED OTATEOT ATENT	AND HADEMANN	3				
In re Patent Application of:							
Young-Min CHEON	G, et al.						
Application No.: 09	/776,706	Group Art Unit: 2651					
Filed: February 6, 2	2001	Examiner:					
For: OPTICAL R	For: OPTICAL READING AND WRITING SYSTEM						
	INFORMATION DISCLOS	URE STATEMENT	RECEIVED				
Commissioner for F	Patents		NOV 1 7 2003				
P.O. Box 1450 Alexandria, VA 223	313-1450		Technology Center 2600				
Sir:							
In accordance with the duty of disclosure provisions of 37 CFR § 1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application. 1. Enclosures accompanying this Information Disclosure Statement are:							
1a. ⊠ 1b. ⊠ 1c. ⊠ 1d. ⊠ 1e. □ 1f. □ 1g. □	Form PTO-1449. Copies of IDS citations. An English language copy of seapplication or a PCT Internation English language translation (A language publication. Explanations of Relevancy of Reproviding a concise explanation List of Copending Applications List of Additional Submitted Doc	earch report(s) from a nal Search Report. bstract Only) attached references (ATTACHN n of each non-English (ATTACHMENT 1(f), I	counterpart foreign d to each non-English MENT 1(e), hereto) for publication. hereto).				
2.							
	(Check either Item 2a						
2a. 🗌	Within three months of the filing Continued Prosecution Applicat	•	oplication other than a				
2b.	Within three months of the date		al stage as set forth in				

§ 1.491 in an international application.

Continued Examination under § 1.114.

Before the mailing of a first Office Action on the merits; or

Before the mailing of a first Office Action after the filing of a Request

Serial No.: 09/776,706

3.	specified Action und	mation Disclosure Statement is filed under 37 CFR § 1.97(c) after the period in paragraph 2 above but before the mailing date of any of a Final Office der § 1.113, a Notice of Allowance under § 1.311 or an action that otherwise esecution in the application, AND (Check either Item 3a or 3b; Item 3b to be checked if any reference known for more than 3 months) The §1.97(e) Statement in Item 5 below is applicable; OR The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is: enclosed. to be charged to Deposit Account No. 19-3935.	
4.		mation Disclosure Statement is filed under 37 CFR §1.97(d) after the period in paragraph 3 above, but on or before payment of the Issue Fee, AND The § 1.97(e) Statement in Item 5 below is applicable; AND The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is: enclosed.	
		to be charged to Deposit Account No. 19-3935.	
5.	Statemen 5a. 5b.	information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.	
6.	This is a 0	continuation/divisional/continuation-in-part application under 37 CFR §	
		(Check appropriate Items 6a and/or 6b)	
	 6a. 🗌	Copies of the publications listed on the attached Form PTO-1449 which were previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, have been omitted pursuant to 37 CFR	
	6b. 🗌	§ 1.98(d). Copies of the publications listed on the attached Form PTO-1449 which were not previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, are provided herewith.	

Serial No.: 09/776,706

7.	П	This is a	continuation/divisional application under 37 CFR § 1.53(d) or Request for	
۲.	Continued Examination under 37 CFR 1.114. (Check either Item 7a or 7b)			
			(Check either Item 7a or 7b)	
		7a. 🔲	The Issue Fee has not been paid.	
		7b. 🔲	A Petition to Withdraw from issue under 37 CFR §1.313(c) is filed concurrently herewith or has been granted. A continuation application	
			under 37 CFR § 1.53(d) or Request for Continued Examination under 37	
			CFR 1.114, after payment of the Issue Fee is proper in accordance with 37	
			CFR § 1.53(d)(1)(ii) or 37 CFR 1.114(a), respectively.	
8.		This is a	Supplemental Information Disclosure Statement.	
			(Check either Item 8a or 8b)	
		8a. 🗌	This Supplemental Information Disclosure Statement under 37 CFR § 1.97(f) supplements the Information Disclosure Statement filed on A bona fide attempt was made to comply with 37 CFR § 1.98, but inadvertent	
			omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental IDS can	
		ob 🗆	be considered as if properly filed on This Supplemental Information Disclosure Statement is timely filed within	
		8b. 🗌	one (1) month of the Notice under 37 CFR § 1.97 and 1.98, mailed	
			(MPEP 609 C(1), Form ¶ 6.49, Rev. 1, Feb. 2000, pp. 600-107)	
9.			nce with 37 CFR § 1.98, a concise explanation of what is presently	
	understood to be the relevance of each non-English language publication is:			
		• 57	(Check appropriate Items 9a, 9b, 9c and/or 9d)	
		9a. 🛚	satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office. (See U.S. Patent &	
			Trademark Office's authorization in the Federal Register, Vol. 57, No. 12, January 17, 1992, at page 2031 (Reply to Comment 68).)	
		9b. 🔲	set forth in the application.	
		9c. 🛚	satisfied because an English language translation (Abstract Only) is	
		9d. 🔲	attached to each non-English language publication. enclosed as Attachment 1(e), hereto.	
10.	b	e, material	on is made that the information cited in this Statement is, or is considered to to patentability nor a representation that a search has been made (other	
			report(s) from a counterpart foreign application or a PCT International ort, if submitted herewith). 37 CFR §§ 1.97(g) and (h).	
	. 3	caron izab	ord ii gapturgod udromuriki or jotiv 22 not (A) aria (u)	

Serial No.: 09/776,706

11. The Commissioner is authorized to credit any overpayment or charge any additional fee required under 37 CFR § 1.17 for this Information Disclosure Statement and/or Petition to Deposit Account No. 19-3935.

Respectfully submitted,

STAAS & HALSEY LLP

Registration No. 37,240

Dated: 11/14/03

1201 New York Ávenue, N.W.

Suite 700

Washington, D.C. 20005 Telephone: (202) 434-1500 Facsimile: (202) 434-1501